Japan's health ministry on Wednesday approved a blood test developed by Fujirebio that helps diagnose Alzheimer's disease, a simpler option for a country with the world's oldest population and a rising number of dementia cases.
The approval covers manufacture and sale of the test, parent company HU Group Holdings announced. It is intended for use as a diagnostic aid, Kyodo News reported.
In Alzheimer's, proteins called amyloid beta and tau build up in the brain and destroy nerve cells, lowering cognitive function. The Fujirebio test measures tau concentration in blood plasma to assess whether amyloid beta is accumulating.
Existing methods require analysis of cerebrospinal fluid, which is physically taxing for patients and expensive. Fujirebio applied to the ministry for approval in November last year.
The ministry expects the simpler test to allow doctors to grasp the state of the brain quickly. For families and clinicians, a blood draw replaces a procedure that until now meant a lumbar puncture.